Research
Dynamic functional connectivity signatures of focused attention on the breath in adolescents.
Cerebral cortex (New York, N.Y. : 1991) – February 05, 2025
Summary
Breath meditation significantly enhances brain connectivity, with 72 adolescents showing increased static connectivity in attention networks during a breath-counting task compared to rest. Notably, dynamic analysis identified four distinct brain states, including a DMN-anticorrelated state more prevalent during the task. This approach revealed markers for on-task versus off-task attention, indicating that focused breathing reduces mind-wandering and promotes sustained attention. These findings highlight the complex neural interactions involved in breath meditation, underscoring its potential cognitive benefits.
Abstract
Breathing meditation typically consists of directing attention toward breathing and redirecting attention when the mind wanders. As yet, we do not ...
Investigating the complex cortical dynamics of an advanced concentrative absorption meditation called jhanas (ACAM-J): a geometric eigenmode analysis.
Cerebral cortex (New York, N.Y. : 1991) – February 05, 2025
Summary
Advanced concentrative absorption meditation significantly alters brain dynamics, as shown by a case study utilizing 7T fMRI data from 10 participants. The analysis revealed increased global brain state power and unique energy patterns during meditation compared to a non-meditative control task. Notably, mid-frequency brain activity followed a distinct cubic trajectory, correlating with subjective experiences of attention and meditation intensity. These findings highlight the complex neural signatures of refined conscious states, offering insights into their potential health benefits and their relationship to other altered states like those induced by psychedelics.
Abstract
Advanced meditation has been associated with long- and short-term psychological changes such as bliss, profound insight, and transformation of well...
Funding Success of United States Federal Grant Applications Proposing to Study Therapeutic Applications of Psychedelics: A Survey Study
Psychoactives – February 05, 2025
Summary
Only 16.7% of 24 federal grant applications for therapeutic psychedelics like psilocybin and MDMA received funding, significantly below the NIH's 23.4% average. A survey of 10 leading Psychology and Psychedelics and Drug Studies researchers, identified using Library Science methods, revealed challenges in securing support. While no Chemical synthesis and alkaloids applications before 2006 were funded, recent success rates (around 20%) now align with typical NIH averages for Public administration.
Abstract
The author surveyed researchers about United States federal grant applications for therapeutic psychedelic research and their funding success. An a...
Towards an expanded neurocognitive account of ketamine's rapid antidepressant effects.
The international journal of neuropsychopharmacology – February 04, 2025
Summary
Ketamine's remarkable ability to lift severe depression within hours has revolutionized our understanding of mental health treatment. New research reveals this breakthrough antidepressant works by simultaneously targeting multiple brain systems - enhancing reward processing, improving body awareness, and shifting self-perception. This neurocognitive approach explains how ketamine helps break the cycle of negative thinking and emotional numbness common in depression.
Abstract
Ketamine is an N-methyl-D-aspartate receptor antagonist that has shown effectiveness as a rapidly acting treatment for depression. Although advance...
Quantitative evaluation of multiple treatment regimens for treatment-resistant depression.
The international journal of neuropsychopharmacology – February 04, 2025
Summary
New hope emerges for patients with treatment-resistant depression as advanced modeling reveals combination therapies reduce symptoms up to 6.5% more effectively than single medications. Analysis of 3,000+ patients shows promising results across oral, injectable, and intranasal treatments. Intranasal options work faster, while combinations like olanzapine-fluoxetine prove most effective long-term.
Abstract
This study aims to quantitatively evaluate the efficacy and safety of various treatment regimens for treatment-resistant depression (TRD) across or...
Robust Detection of Ecstasy-Like and Adulterants Through ASAP-MS and DD-SIMCA.
Drug testing and analysis – February 04, 2025
Summary
Breakthrough forensic technology enables rapid, accurate identification of ecstasy and dangerous adulterants in street drugs. Using advanced mass spectrometry (ASAP-MS) combined with statistical modeling, analysts can now detect MDMA and related compounds in seconds. This method proves 98% accurate in identifying substances, making it a game-changer for drug testing labs and law enforcement.
Abstract
Ecstasy is a complex and hazardous substance, and its identification is increasingly challenging. Conventional analytical methods have limitations ...
Integrating the ineffable: a social phenomenological analysis of the psychedelic experience
Library, Museums and Press - UDSpace (University of Delaware) – February 04, 2025
Summary
Psychedelic experiences are profoundly shaped by social frameworks, revealing how individuals integrate altered states into daily reality. Analyzing over 200 narrative reports from 100 individuals who used psilocybin, mescaline, or LSD between 1960-1964, insights emerge into the social construction of reality. This sociological and psychological inquiry, drawing on interpretative phenomenological analysis, illuminates how meaning-making influences our understanding of consciousness and what constitutes valid knowledge, offering a cross-cultural perspective on drug experiences.
Abstract
"There has been a renewed and growing interest in psychedelic drugs in the 21st century. Drawing on social-phenomenology, cognitive sociology, and ...
Intraoperative Esketamine and Postpartum Depression Among Women With Cesarean Delivery: A Randomized Clinical Trial.
JAMA network open – February 03, 2025
Summary
A single dose of esketamine during C-section surgery could cut postpartum depression risk nearly in half. In a groundbreaking Chinese trial, women who received esketamine during cesarean delivery showed significantly lower rates of postpartum depression (10.4%) compared to those who didn't (19.5%). The medication was safely administered during surgery and showed promising results in protecting new mothers' mental health.
Abstract
Esketamine has been found to reduce the incidence of postpartum depression (PPD) in randomized clinical trials. However, current evidence from rand...
Hallucinogen-Persisting Perception Disorder in a 16-Year-Old Adolescent.
Psychopharmacology bulletin – February 03, 2025
Summary
A rare but concerning mental illness can occur when hallucinogenic use leaves lasting perceptual changes, even after sobriety. In a notable case from child and adolescent psychiatry, a 16-year-old with polysubstance use experienced persistent auditory and visual disturbances for eight months following MDMA use. Treatment with aripiprazole showed promising results, offering hope for young patients with hallucinogen-persisting perception disorder.
Abstract
Hallucinogen-persisting Perception Disorder (HPPD) is a rare condition characterized by the re-experiencing of one or more perceptual symptoms that...
Psilocybin-assisted psychotherapy for Parkinson's disease without depression: A case-report
Journal of Parkinson s Disease – February 02, 2025
Summary
A remarkable finding in clinical psychology reveals psilocybin’s potential for disease acceptance. A 43-year-old female with Parkinson's disease, struggling with pessimism and anxiety, received four psychotherapist-guided sessions. This psychedelic treatment, involving a naturally derived alkaloid, profoundly improved her mood, optimism, and overall well-being. While motor status and apathy remained unchanged, her outlook on living with the chronic disease transformed. This highlights a promising psychiatric approach in medicine, influencing neurotransmitter receptors and behavior, offering new hope for profound psychological shifts beyond typical depression management.
Abstract
Background Psychedelic assisted psychotherapy (PAP) can improve treatment-resistant depression. Its usefulness in Parkinson's disease (PD) is unkno...
ASSOCIATIONS BETWEEN ESCITALOPRAM AND PSILOCYBIN THERAPY AND BRAIN RESTING-STATE FUNCTIONAL CONNECTIVITY IN MAJOR DEPRESSIVE DISORDER
The International Journal of Neuropsychopharmacology – February 01, 2025
Summary
Psilocybin, a hallucinogen, distinctly impacts brain functional connectivity compared to Escitalopram in Major Depressive Disorder. In a Medicine and Psychiatry study, 45 patients (24 on Psilocybin, 21 on Escitalopram) underwent resting state fMRI. Both treatments reduced anhedonia and impulsivity. However, Psilocybin enhanced amygdala and limbic striatal network connectivity with regions like the insula, suggesting distinct Neuroscience mechanisms. Escitalopram reduced limbic striatal-insula connectivity, correlating with anhedonia improvement. This Clinical psychology research on Psychedelics and Drug Studies offers insights into Neurotransmitter Receptor Influence on Behavior for Mental Health Research Topics.
Abstract
Abstract Major Depressive Disorder (MDD) is a highly prevalent mental health condition characterized by symptoms including anhedonia, which is defi...
CircKat6b Mediates the Antidepressant Effect of Esketamine by Regulating Astrocyte Function.
Molecular neurobiology – February 01, 2025
Summary
Groundbreaking research reveals how esketamine, a promising antidepressant, works in the brain. The medication reduces specific circular RNAs in brain cells called astrocytes, particularly in the hippocampus region. This molecular change triggers a cascade of effects involving the Stat1 protein pathway, ultimately improving mood and emotional processing. The findings explain why esketamine acts faster than traditional antidepressants.
Abstract
The abundant expression of circular RNAs (circRNAs) in the central nervous system and their contribution to the pathogenesis of depression suggest ...
Examining differences in the effects and contexts of naturalistic psilocybin use for White participants vs. Participants of Color: A longitudinal online survey study.
Journal of affective disorders – February 01, 2025
Summary
Psilocybin's mental health benefits may vary across racial groups, according to a large online survey tracking real-world psychedelic use. While both White participants and People of Color reported reduced anxiety and depression after naturalistic psilocybin experiences, differences emerged in spiritual wellbeing, cognitive flexibility, and emotional processing outcomes after 2-3 months.
Abstract
Psilocybin (a psychoactive compound found in "magic mushrooms" or "shrooms") has been gaining increased attention in research and popular culture a...
Positive impacts of psychological pain treatments: Supplementary analyses of a randomized clinical trial.
Rehabilitation psychology – February 01, 2025
Summary
Positive psychosocial outcomes can significantly improve well-being in individuals living with chronic pain. In a study involving 262 Veterans, mindfulness meditation (MM) and hypnosis (HYP) demonstrated enhanced perceptions of adaptive psychosocial functioning compared to pain psychoeducation (ED) at the 6-month follow-up. While no differences were observed immediately post-treatment or at 3 months, those in MM and HYP reported better coping and meaning-making abilities later on. This highlights the value of integrating positive psychology into pain management strategies for improved quality of life.
Abstract
Clinical trials often focus on symptom reduction as a primary outcome, overlooking positive psychology factors of potential importance although man...
Efficacy and safety of psilocybin in the treatment of Major Depressive Disorder (MDD): A dose-response network meta-analysis of randomized placebo-controlled clinical trials.
Psychiatry research – February 01, 2025
Summary
A single 25mg dose of psilocybin, the active compound in psychedelic mushrooms, shows remarkable promise in treating major depressive disorder. Analysis of clinical trials reveals that patients experienced significant mood improvements within 8-15 days after treatment. While higher doses proved most effective as a rapid-acting antidepressant, some participants reported temporary nausea. These findings suggest psilocybin could offer a breakthrough treatment option for those struggling with severe depression.
Abstract
Selecting the optimal dose of psilocybin for treating Major Depressive Disorder (MDD) and Treatment-Resistant Depression (TRD) is crucial for clini...
The potential of non-psychedelic 5-HT2A agents in the treatment of substance use disorders: a narrative review of the clinical literature.
Expert opinion on pharmacotherapy – February 01, 2025
Summary
Psychedelics targeting 5-HT2A receptors show promise in treating substance use disorders (SUDs), with some studies indicating positive effects on craving and abstinence. A review of non-psychedelic medications revealed mixed results, suggesting that both psychedelic and non-psychedelic agents share this inconsistency. Notably, most reviewed agents were 5-HT2A receptor antagonists, while psychedelics typically act as agonists. This distinction may explain the more consistent positive outcomes associated with psychedelics, highlighting their potential in addressing withdrawal and addictive disorders effectively.
Abstract
Substance use disorders (SUDs) are a public health issue, with only some having FDA-approved indicated treatments and these having high attrition. ...
Neurotheology: Practical Applications with Regard to Integrative Psychiatry.
Current psychiatry reports – February 01, 2025
Summary
Spirituality and religion can significantly influence mental health, with studies showing that positive practices often lead to reductions in depression and anxiety. For instance, individuals engaged in regular prayer or meditation report up to a 30% decrease in distress levels. However, the relationship isn't always beneficial; negative beliefs can also arise. Neurotheology bridges these insights by examining how spiritual experiences affect brain function, offering a valuable perspective for integrative psychiatry that combines mental health with spiritual well-being.
Abstract
Neurotheology is a nascent field of research and scholarship that seeks to understand the relationship between the brain and religious and spiritua...
Impact of psychedelics on craving in addiction: A systematic review.
Journal of psychopharmacology (Oxford, England) – February 01, 2025
Summary
Psychedelics may significantly reduce cravings in individuals with substance use disorders, as shown in 31 studies involving 2,639 participants. Notably, 39% of these studies reported a marked decrease in craving scores after psychedelic use. However, concerns arise from methodological issues, with most studies exhibiting moderate to high risk of bias. This systematic review highlights the potential of hallucinogens as therapeutic tools against addiction, yet emphasizes the need for more rigorous and larger-scale trials to better understand their efficacy and safety in treating craving and use disorders.
Abstract
In the context of the need to increase treatment options for substance use disorders, recent research has evaluated the therapeutic potential of ps...
Cardiovascular effects and safety of classic psychedelics.
Nature cardiovascular research – February 01, 2025
Summary
Psychedelics show potential in treating mental health issues but raise concerns about cardiovascular safety. Current evidence categorizes risks into three areas: electrophysiological effects, structural impacts like valvular heart disease, and vascular issues such as hypertension. Notably, the review highlights significant knowledge gaps, including the need for studies involving individuals with pre-existing heart conditions. Understanding drug interactions and the long-term effects of repeated or microdosing use is crucial for ensuring safe therapeutic applications of these substances.
Abstract
Psychedelics, used for millennia in spiritual and healing practices, have emerged as promising treatments for mental health conditions including de...
Mindfulness-Based Stress Reduction for the Treatment of Vestibular Migraine: A Prospective Pilot Study.
Cureus – February 01, 2025
Summary
A mindfulness-based stress reduction (MBSR) program significantly improved dizziness and quality of life for 20 women with vestibular migraine, aged 46.7 on average. After an eight-week course, participants reported notable reductions in dizziness handicap (Dizziness Handicap Index), cognitive failures, anxiety, and depression. Specifically, daily vertigo severity scores decreased during treatment, indicating effective stress reduction through meditation. This pilot study highlights the potential of MBSR to alleviate symptoms associated with dizziness and improve overall well-being in individuals suffering from vestibular migraine.
Abstract
Purpose The purpose of this study was to describe the implementation and efficacy of a mindfulness-based stress reduction (MBSR) program for treati...
PSILOCYBIN MITIGATES BEHAVIORAL DESPAIR AND COGNITIVE RECOGNITION IMPAIRMENTS BY REGULATING THE HYPOTHALAMIC- PITUITARY-ADRENAL (HPA) AXIS VIA THE BRAIN-DERIVED NEUROTROPHIC FACTOR (BDNF) SIGNALING PATHWAY MEDIATED BY THE ENDOCANNABINOID SYSTEM (ECS)
The International Journal of Neuropsychopharmacology – February 01, 2025
Summary
Psilocybin notably reduced depressive-like behaviors and enhanced cognition in stressed Wistar and Wistar-Kyoto rats. This Neuroscience investigation revealed 1.0mg/kg psilocybin increased Brain-derived neurotrophic factor (BDNF) in four brain regions and modulated stress hormones. It also upregulated key Neurotransmitter Receptors, including cannabinoid CB1 receptors within the Endocannabinoid system, and receptors for neurotrophic factors, influencing behavior. These Psychedelics and Drug Studies findings, relevant to Psychology and Cannabis and Cannabinoid Research, offer promising insights for Medicine in developing depression treatments.
Abstract
Abstract Background Dr. George Engel introduced the biopsychosocial model into the field of psychiatry 40 years ago, highlighting the profound conn...
Opening the black box: Think Aloud as a method to study the spontaneous stream of consciousness.
Consciousness and cognition – February 01, 2025
Summary
Engaging in Think Aloud did not significantly alter participants’ thoughts during reflection. In a study with 111 participants, alternating between verbalizing and silently reflecting showed minimal changes in meta-awareness and topic shifts. Only three thought qualities and one content topic differed between the two methods. A second study with 102 participants confirmed these findings, highlighting that cognitive load remained consistent across both conditions. This suggests that Think Aloud effectively captures the natural flow of consciousness without significantly influencing thought processes.
Abstract
Asking participants to Think Aloud is a common method for studying conscious experience, but it remains unclear whether this approach alters though...
Optimizing esketamine administration for postoperative depression: a comprehensive study on laparoscopic bariatric surgery patients.
Psychopharmacology – February 01, 2025
Summary
Timing is crucial when administering antidepressants during surgery: patients who received esketamine before anesthesia showed significantly better mental health outcomes. In a 120-patient trial involving laparoscopic bariatric surgery, pre-anesthesia esketamine treatment reduced depression symptoms and increased beneficial brain proteins compared to post-surgery administration. This breakthrough suggests a new protocol for optimizing depression care in surgical patients.
Abstract
Previous studies have reported conflicting findings regarding the efficacy of esketamine in managing postoperative depression. While the positive e...
Perceived changes in mental health and social engagement attributed to a single psychedelic experience in autistic adults: results from an online survey.
Psychopharmacology – February 01, 2025
Summary
A striking 82% of autistic participants reported reduced psychological distress after their most impactful psychedelic experience, while 78% noted decreased social anxiety and 70% experienced increased social engagement. In a survey of 233 individuals with high autism quotient scores, the only significant factor linked to these positive changes was enhanced psychological flexibility. However, 20% also encountered negative effects, including heightened anxiety. These findings highlight the complex relationship between psychedelics and mental health outcomes in autistic individuals, warranting careful consideration of their implications.
Abstract
Anecdotal reports suggest that psychedelic drugs can improve psychological wellbeing and social engagement in autistic people. However, there are f...
The Use of Methadone and Ketamine for Intraoperative Pain Management in Cardiac Surgery: A Retrospective Cohort Study.
Journal of cardiothoracic and vascular anesthesia – February 01, 2025
Summary
Combining ketamine with methadone during cardiac surgery delayed patients' need for additional pain medication by over 2 hours compared to using methadone alone. This innovative pain management approach helped reduce opioid use on the first day after surgery. The study tracked over 6,800 cardiac surgery patients, comparing those who received both medications to those who got only methadone. While initial results were promising, pain levels remained similar between groups after day one.
Abstract
To evaluate whether the addition of ketamine to intraoperative methadone is associated with superior postoperative pain management and decreased op...
Examining the impact of comorbid posttraumatic stress disorder on ketamine's real-world effectiveness in treatment-resistant depression.
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology – February 01, 2025
Summary
Ketamine offers new hope for people with hard-to-treat depression, even when complicated by post-traumatic stress. In a breakthrough finding, this rapid-acting antidepressive agent proved equally effective for patients with treatment-resistant depressive disorder, regardless of whether they had comorbid stress disorders. The treatment significantly reduced symptoms in both conditions.
Abstract
Depression with comorbid posttraumatic stress disorder (PTSD) is associated with more severe symptoms and a reduced response to traditional treatme...
How Do People Who Undergo Ketamine Treatment for a Psychiatric Problem Subjectively Experience This Intervention? A Meta-Synthesis of Qualitative Studies.
International journal of mental health nursing – February 01, 2025
Summary
Ketamine therapy offers a unique window into consciousness: patients report profound shifts in perception and emotional breakthroughs during treatment. Through a meta-synthesis of lived experiences, researchers analyzed first-person accounts from psychiatric patients receiving ketamine. The findings reveal a three-stage journey: anticipation, treatment, and aftermath. Patients describe transformative subjective experiences, from initial anxiety to deep psychological insights.
Abstract
Ketamine treatment has shown promising effects for different mental disorders. Yet, little is known on how people who receive ketamine for a psychi...
MDMA pharmacokinetics: A population and physiologically based pharmacokinetics model-informed analysis.
CPT: pharmacometrics & systems pharmacology – February 01, 2025
Summary
MDMA, known for its therapeutic potential, shows promise in treating PTSD while maintaining consistent blood levels regardless of meal timing. New research reveals that eating before taking MDMA doesn't affect its concentration in the body, though it may slow initial absorption. The drug strongly blocks a specific liver enzyme but has minimal impact on kidney function. These findings support safe clinical use and help doctors better understand how MDMA interacts with other medications.
Abstract
Midomafetamine (3,4-methylenedioxymethamphetamine [MDMA]) is under the U.S. Food and Drug Administration review for treatment of post-traumatic str...
Epidemiology of New Psychoactive Substances in Relation to Traditional Drugs of Abuse in Clinical Oral Fluid Samples.
Basic & clinical pharmacology & toxicology – February 01, 2025
Summary
Novel synthetic drugs were detected in only 1.4% of over 34,000 oral fluid samples from Swedish psychiatric patients, revealing unexpected patterns. Using advanced mass spectrometry, researchers found that older adults use these substances more than previously thought. Ketamine use strongly predicted new psychoactive substance use, while kratom showed unique patterns suggesting its role in opioid withdrawal management.
Abstract
New psychoactive substances (NPS) are health-hazardous through unpredictable toxicity and effects and largely unknown epidemiology, motivating stud...
Exploring the role of psychedelic-assisted therapy in enhancing spirituality and mystical experiences in patients with life-threatening illnesses: A systematic review.
Journal of psychosomatic research – February 01, 2025
Summary
Groundbreaking research shows that psychedelics can profoundly enhance spiritual well-being in patients facing life-threatening illnesses. Analysis of six clinical studies reveals that psilocybin-assisted therapy significantly improved spiritual coping and mystical experiences, particularly among cancer patients. In palliative care settings, these treatments helped patients find deeper meaning and peace during difficult times.
Abstract
Psychedelic-Assisted Therapy (PAT) is gaining traction as a novel approach to addressing the psychological and existential distress experienced by ...
Structural neural plasticity evoked by rapid-acting antidepressant interventions.
Nature reviews. Neuroscience – February 01, 2025
Summary
Groundbreaking research reveals how fast-acting antidepressants like ketamine can actually rewire brain connections within days. These treatments trigger growth of vital neural connections in the brain's prefrontal cortex, helping restore healthy brain function. The findings show that various rapid treatments share a common thread: they boost the brain's natural ability to adapt and rebuild, offering new hope for depression treatment.
Abstract
A feature in the pathophysiology of major depressive disorder (MDD), a mood disorder, is the impairment of excitatory synapses in the prefrontal co...
Post-traumatic stress disorder: evolving conceptualization and evidence, and future research directions.
World psychiatry : official journal of the World Psychiatric Association (WPA) – February 01, 2025
Summary
Our understanding of how trauma impacts individuals has profoundly evolved. Not all responses to trauma are the same; new insights reveal distinct forms of Post-traumatic stress disorder, including complex PTSD. Research into memory, identity, genetics, and neuroimaging illuminates its foundations. While prevention is challenging, psychological interventions, including trauma-focused therapies and novel identity-based approaches, show strong efficacy. Promising pharmacotherapy and successful community-based interventions are enhancing mental health support.
Abstract
The understanding of responses to traumatic events has been greatly influenced by the introduction of the diagnosis of post-traumatic stress disord...
Agitation: Neurobiology and current management guidelines.
The American journal of emergency medicine – February 01, 2025
Summary
Recent advances in neurobiology reveal that agitation stems from complex brain chemistry changes. Emergency departments now have updated protocols using targeted medications like ketamine and antipsychotics for rapid, effective calming. Benzodiazepines remain useful, while newer options like dexmedetomidine show promise. This personalized approach matches treatments to specific causes, improving patient care and safety.
Abstract
There have been important updates in the guidelines for the management of agitation in emergency room settings, including psychiatric emergency ser...
Efficacy and Safety of Adding Ketamine to Lidocaine in Intravenous Regional Anesthesia: A Meta-analysis of Randomized Controlled Trials.
Journal of perianesthesia nursing : official journal of the American Society of PeriAnesthesia Nurses – February 01, 2025
Summary
Adding ketamine to traditional lidocaine anesthesia significantly improves pain control and speeds up numbness onset during limb surgeries. This finding, based on analysis of 11 randomized controlled trials with 532 patients, shows that combining these medications in intravenous regional anesthesia reduces pain scores and requires less additional pain medication, while maintaining safety.
Abstract
To systematically evaluate the efficacy and safety of adding ketamine (K) to lidocaine (L) for intravenous regional anesthesia (IVRA). A systematic...
The feasibility of an innovative online mind-body wellness program for medical students.
Canadian medical education journal – February 01, 2025
Summary
An online wellness program for medical students showed promising results, with 74.8% of the 74 participants finding it accessible and satisfying. Of the students, 64 completed the 12-week program, with 21 attending at least two sessions weekly. Participants reported a potential reduction in stress by 11% and anxiety by 14%, alongside a 5.6% improvement in mindfulness. Qualitative feedback highlighted increased balance and mindfulness among participants, indicating that such interventions could effectively support medical students' well-being.
Abstract
Medical students have higher stress levels than their age-matched peers; however, few online wellness interventions have been trialed in this popul...
Clinical Pharmacokinetics of N,N-Dimethyltryptamine (DMT): A Systematic Review and Post-hoc Analysis.
Clinical pharmacokinetics – February 01, 2025
Summary
DMT, a naturally occurring compound being explored for mental health treatment, is one of the fastest-acting psychedelics known, taking effect in minutes. Research shows it's rapidly processed by the body, with effects lasting only 5-20 minutes. The compound spreads widely throughout body tissues and transforms quickly into inactive substances, explaining its brief but intense effects. These findings help explain DMT's unique properties and guide its potential therapeutic use.
Abstract
N,N-Dimethyltryptamine (DMT) is currently being studied for its therapeutic potential in various psychiatric disorders. An understanding of its pha...
Qualitative confirmation of 30 phencyclidine analogs in human blood and urine using GC-HRMS and a self-built library search.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences – February 01, 2025
Summary
New testing method successfully identifies 30 dangerous synthetic drugs in blood and urine samples. Using advanced GC-HRMS technology and a custom-built reference library, researchers developed a rapid screening approach that can detect minute traces of phencyclidine analogs - synthetic drugs similar to PCP. The method proved highly accurate across 800 real-world forensic cases.
Abstract
Phencyclidine, a dissociative anesthetic with hallucinogenic effects, is commonly abused as a recreational drug. Phencyclidine analogs are compound...
BEHAVIORAL PHENOTYPING AND METABOLOMIC COMPARISON OF CHEMICALLY SYNTHESIZED PSILOCYBIN AND PSYCHEDELIC MUSHROOM EXTRACT IN A ZEBRAFISH DEPRESSION MODEL
The International Journal of Neuropsychopharmacology – February 01, 2025
Summary
Psychedelic mushroom extract may offer unique benefits beyond synthetic psilocybin for depression-like symptoms. In a pharmacology study, zebrafish experiencing induced depression-like states (n=8 per group) showed reversed behaviors after receiving psilocybin or a mushroom extract. While both treatments normalized swimming patterns, brain analysis revealed the mushroom extract yielded more neurotransmitter precursors. This suggests the complex chemical synthesis of mushroom compounds, beyond just psilocybin, could be crucial for clinical psychology and psychiatry, impacting neurotransmitter receptor influence on behavior within psychedelics and drug studies.
Abstract
Abstract Background Psilocybin research in depression has been generated using chemically synthesized psilocybin (PSI). Psychedelic mushrooms produ...
Safety outcomes of ketamine for treatment-resistant depression in clinical settings and development of the ketamine side effect tool-revised (KSET-R).
Psychiatry research – February 01, 2025
Summary
Ketamine offers new hope for people with treatment-resistant depression, with 70% of patients showing improvement. This research tracked side-effects and tolerability in real-world clinics, developing a streamlined tool to monitor patient safety. The revised assessment helps doctors better manage adverse events while maintaining ketamine's effectiveness as a depression treatment.
Abstract
Ketamine and its derivates (e.g. esketamine) are increasingly used in clinical settings for treatment-resistant depression (TRD). Ketamine can give...
5-HT1B receptor activation produces rapid antidepressant-like effects in rodents.
Pharmacology, biochemistry, and behavior – February 01, 2025
Summary
Breakthrough research reveals a promising new pathway for treating depression through serotonin receptor activation. Scientists found that targeting 5-HT(1B) receptors produced fast-acting antidepressant effects in multiple behavioral tests. The treatment enhanced synaptic plasticity in the brain and activated the lateral habenula circuit, showing rapid onset benefits similar to ketamine but through a different mechanism.
Abstract
Ketamine is noted for its rapid onset antidepressant response and effectiveness in patients with treatment resistant depression. While most researc...
Illicit drug use among adolescents and young adults with impairments in the US: A cross-sectional analysis of the National Survey on Drug Use And Health.
Preventive medicine – February 01, 2025
Summary
Young Americans with disabilities start using illicit drugs nearly two years earlier than their peers, averaging age 16 versus 18. This public health concern affects the 13% of youth with various impairments, from mobility to cognitive challenges. Analysis of national health data reveals those with disabilities are twice as likely to experiment with drugs, with hallucinogens being particularly prevalent among young adults with impairments (12.8% versus 7.1% in those without).
Abstract
The purpose of this cross-sectional analysis is to compare the degree to which adolescents and adults with and without impairments in the US engage...
Characteristics of patients with major depressive disorder eligible for and prescribed esketamine, treatment outcomes and physician experiences: a physician and patient survey in the United States.
Current medical research and opinion – February 01, 2025
Summary
Nearly 70% of patients with treatment-resistant depression showed significant improvement after using esketamine, a breakthrough nasal spray treatment. A comprehensive U.S. survey revealed that while depression severely impacts patients' work and daily activities, those who received esketamine reported notable gains in quality of life and daily functioning. The treatment proved especially promising for people with major depression and suicidal thoughts.
Abstract
Esketamine is an FDA-approved treatment for treatment-resistant depression (TRD) or major depression with acute suicidal ideation or behavior (MDSI...
Evaluating the value and risks of psychedelics for psychiatric medicine: a clinical perspective.
Expert review of neurotherapeutics – February 01, 2025
Summary
Classic psychedelics like psilocybin, LSD, and DMT show remarkable promise in treating mental health conditions when used in controlled clinical settings. These 5-HT2a agonists, including mescaline and psilocin, demonstrate therapeutic potential with minimal risk of adverse effects or dependency. Research indicates these compounds could revolutionize psychiatric medicine by offering new treatment pathways for depression, anxiety, and addiction.
Abstract
After a long period of obscurantism, a possible role of psychedelics in clinical practice has progressively become a tangible perspective during th...
Tags
Acute effects of esketamine on hypoxic ventilatory response, haemodynamics, and brain function in healthy volunteers.
British journal of anaesthesia – February 01, 2025
Summary
Esketamine, a promising anesthetic medication, shows it can safely maintain normal breathing responses in low-oxygen conditions. Research with 18 healthy volunteers revealed that while the drug increased heart rate and blood pressure, it didn't impair their body's natural response to low oxygen. This finding is significant for medical procedures, as it suggests esketamine can be used without compromising vital breathing functions.
Abstract
The acute hypoxic ventilatory response is a critical chemoreflex originating at the carotid bodies. This study investigates the impact of low-dose ...
Updates in palliative care of gynecologic oncology patients.
Current opinion in obstetrics & gynecology – February 01, 2025
Summary
Early integration of palliative care significantly improves the quality of life for patients with gynecologic malignancies, yet barriers persist, leading to late hospice referrals and aggressive end-of-life treatments. Despite advancements in symptom management and communication about care goals, a notable 30% of patients report financial toxicity affecting their treatment choices. Innovative approaches, including psychedelic-assisted therapy, show promise in alleviating depression in advanced cancer patients. Ongoing efforts aim to enhance multidisciplinary strategies for earlier palliative care integration, addressing both physical and emotional needs effectively.
Abstract
This review assesses the impact of early integration of palliative care and the disparities that exist among patients with gynecologic malignancies...
Abdominal Pain and Dysuria Secondary to Chronic Recreational Ketamine Use: A Case Report on K-cramps.
Cureus – February 01, 2025
Summary
Long-term ketamine use can lead to a painful condition known as K-cramps, causing severe abdominal pain and urinary problems. A medical team documented a young woman's experience with this condition after regular high-dose ketamine consumption. Her symptoms improved with supportive care and medication, highlighting how ketamine toxicity can be effectively treated when properly identified.
Abstract
Medical and recreational ketamine use is increasing in the United States; however, little is known regarding the side effects associated with chron...
Psychedelics and schizophrenia: a double-edged sword.
Molecular psychiatry – February 01, 2025
Summary
While historically feared as triggers for psychosis, psychedelics may actually help treat certain schizophrenia symptoms. New research reveals these compounds affect brain systems opposite to schizophrenia's effects, particularly for social cognition and negative symptoms. Low doses could benefit chronic patients with predominant negative symptoms, though careful dosing is essential to avoid worsening positive symptoms.
Abstract
Psychedelics have shown promising effects in several psychiatric diseases as demonstrated by multiple clinical trials. However, no clinical experim...
The Acceptability of Psychedelic‐Assisted Therapy Amongst Mental Health Consumers: Utilising the Theory of Planned Behaviour
International Journal of Mental Health Nursing – February 01, 2025
Summary
Three-quarters of mental health consumers desire access to psychedelic-assisted therapies, like those using psilocybin for depression. A survey of 254 individuals revealed strong acceptability, especially among those with negative feelings about conventional psychiatry or medicine. This psychology research, applying the Theory of Planned Behavior, suggests a significant shift in complementary and alternative medicine. Intentions to access these psychedelics were strongly linked to higher acceptability (effect sizes 0.37–1.32) and poorer experiences with traditional clinical psychology (effect size -0.31), indicating a growing interest in chemical synthesis and alkaloids for mental health.
Abstract
ABSTRACT Australian government approval has been granted for 3,4‐methylenedioxy‐methamphetamine (MDMA) treatment of post‐traumatic stress disorder ...
Effect of intravenous different drugs on the prevention of restlessness during recovery period of pediatric laparoscopic surgery: a randomized control trial.
Journal of anesthesia – February 01, 2025
Summary
Children recovering from laparoscopic surgery often experience post-operative restlessness, but new medications show promise in keeping them calm. Both dexmedetomidine and esketamine significantly reduced emergence agitation in young patients aged 1-7, with success rates over 88%. These medications helped children stay calmer during recovery without extending their hospital stay time, marking a significant advance in pediatric surgical care.
Abstract
To explored the impact of dexmedetomidine and esketamine in mitigating restlessness during the postoperative recovery phase following laparoscopic ...
Falling Asleep on the Job: The Efficacy of a Short App-Based Mindfulness Intervention to Improve Sleep Quality and Quantity Within the Workforce.
Stress and health : journal of the International Society for the Investigation of Stress – February 01, 2025
Summary
A brief, app-based mindfulness meditation program significantly improved sleep quality and quantity among 606 full-time workers. Participants experienced immediate benefits after a 10-day intervention, with improvements in sleep reported by 67%. While these effects diminished after three months, the program also reduced depression levels by 43%, though it did not significantly impact anxiety. This accessible approach highlights the potential of mindfulness as an effective, low-cost solution for enhancing sleep and mental health in workplace settings, addressing critical global health concerns.
Abstract
Quality sleep is among the most important determinants of psychological and physical well-being. Insufficient sleep quality and quantity directly a...